^
Association details:
| Biomarker: | YES1 amplification |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
Published date:
11/26/2021
Excerpt:
Our results indicate that YES1 is also strongly associated with T-DM1 resistance after the development of acquired resistance to trastuzumab, and the continuous inhibition of YES1 is important for overcoming resistance to T-DM1.
DOI:
10.3390/ijms222312809
Source:
Title:
YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer
Published date:
06/23/2020
Excerpt:
We modelled the development of acquired resistance by exposing HER2-positive cells to escalating concentrations of T-DM1. Our study revealed that YES1 amplification conferred resistance to HER2-targeted drugs...
DOI:
10.1038/s41416-020-0952-1
